ARS Pharmaceuticals, Inc. (SPRY) is a San Diego–based biopharmaceutical company best known for neffy, a needle-free intranasal epinephrine spray for severe allergic reactions. After a sharp decline that has left the shares trading near their 52-week low, the question many investors are asking is whether SPRY can reclaim a meaningful share of its former valuation. This article examines whether a move toward a $24 stock price target is realistic and what would have to go right — and wrong — along the way.
The analyst price target picture for SPRY is unusually wide, reflecting genuine disagreement about how quickly neffy's commercial ramp will convert into profits. The most recently published, explicitly named objectives are Leerink Partners' $15 target (maintained with an Outperform rating in early September 2026 after being trimmed from $18) and Cantor Fitzgerald's $30 target (reiterated in August 2026). William Blair also maintains a Buy rating but does not publish a numeric target. Earlier coverage initiations include Roth Capital at $40 and Scotiabank at $30, both from 2025.
Third-party aggregators that track a broader pool of covering analysts report an average stock price target near $24–$25, within a $15–$30 range. That $24 average anchor — a rounded figure — is the central target used throughout this article. It is not an official published consensus, but a calculated mean of the verified current targets, and it sits far below the bullish outliers that once dominated the name.
The latest verified price for SPRY is approximately $3.05, with a 52-week range of $2.91 to $13.15. Reaching $24 would therefore require a gain of roughly 685% — a very large move that would essentially require the company to re-rate from a deeply depressed level back toward levels it traded at only a year ago. The stock currently trades below both its 50-day (around $4.77) and 200-day (around $7.56) moving averages, and the Zacks rating on the name is bearish.
Fundamentally, the company generated roughly $117 million in trailing revenue but remains unprofitable, with a trailing EPS (earnings per share) near -$2.18 and a net loss of about $215 million over the past twelve months. Full-year 2026 revenue is expected to grow to roughly $128 million. Reaching the $24 target would likely require sustained, accelerating neffy adoption, progress toward cash-flow breakeven, and a meaningful expansion of the valuation multiple the market is willing to pay.
SPRY's market structure is decidedly weak. The shares closed near $3.05, just above the 52-week low of $2.91, which now represents the primary support level to watch. A break below that level would open fresh downside risk. On the upside, the first meaningful resistance zone sits in the $3.66–$4.32 area, followed by the 50-day moving average near $4.77 and the 200-day moving average near $7.56. The psychological $10 and prior $13.15 high are far above current levels and would need to be cleared well before the $24 target becomes technically relevant. The relative strength index near the mid-30s suggests the stock is oversold, but oversold conditions alone do not reverse a downtrend.
Analyst price targets typically reflect a roughly 12-month research horizon, though the exact horizon varies by firm and was not disclosed in all cases. Given the wide $15–$40 dispersion, investors should treat the central target as a directional reference rather than a near-term milestone. The most important near-term catalyst is the third-quarter 2026 earnings report scheduled for November 5, 2026, where consensus expects a loss near -$0.34 per share on revenue of about $42 million. Beyond earnings, investors should watch payor formulary decisions, international launch progress, cash runway updates, and any further analyst target revisions, which have been trending lower.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Rather than relying on a single static price target, the tool adapts to evolving price action and momentum, helping traders spot shifting trends, discover new opportunities, and monitor existing positions more efficiently. For a volatile name like SPRY, where sentiment and technical structure can change quickly, an automated, continuously updated signal can provide useful context alongside traditional fundamental research.
Can SPRY reach $24? The arithmetic says the move would be enormous — roughly 685% above the latest verified price near $3.05 — and the current analyst range of $15–$30 shows the Street itself is far from unanimous. The bullish case rests on a genuinely differentiated, first-to-market product in neffy, accelerating revenue, and expanding international and payor access. The bearish case points to persistent losses, rapid cash burn, downward estimate revisions, and a stock mired near multi-year lows. The $24 central target reflects the average of current analyst objectives rather than a guarantee, and reaching it would likely require both sustained commercial execution and a substantial re-rating in investor sentiment. Investors should watch the November 5 earnings report, cash runway disclosures, and any shift in analyst revisions as the most telling indicators of whether such a recovery is taking shape.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, SPRY has been loosely correlated with LPCN. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if SPRY jumps, then LPCN could also see price increases.
| Ticker / NAME | Correlation To SPRY | 1D Price Change % | ||
|---|---|---|---|---|
| SPRY | 100% | +13.33% | ||
| LPCN - SPRY | 63% Loosely correlated | -7.56% | ||
| LXEO - SPRY | 41% Loosely correlated | -2.55% | ||
| KROS - SPRY | 39% Loosely correlated | +1.74% | ||
| TSHA - SPRY | 38% Loosely correlated | -2.17% | ||
| SLDB - SPRY | 37% Loosely correlated | +2.14% | ||
More | ||||